etesevimab

From Aaushi
Jump to navigation Jump to search

Indications

  • treatment of outpatients with COVID-19 >= 14 years of age >= 40 kg
    • especially adults >= 65 years with COVID-19 at risk for severe disease

* must be administered in combination with bamlanivimab

Contraindications

* may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation

Dosage

Mechanism of action

More general terms

References

  1. Gottlieb RL, Nirula A, Chen P et al Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19A Randomized Clinical Trial. JAMA. Published online January 21, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33475701 https://jamanetwork.com/journals/jama/fullarticle/2775647
    Malani PN, Golub RM. Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19. JAMA. Published online January 21, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33475716 https://jamanetwork.com/journals/jama/fullarticle/2775645
  2. Walker M FDA OKs Antibody Combo for Milder COVID-19 - Cut hospitalizations, deaths in patients at high risk of severe disease. MedPage Today February 10, 2021 https://www.medpagetoday.com/infectiousdisease/covid19/91136
  3. 3.0 3.1 American Medical Association (AMA) AMA Morning Rounds. Jan 25, 2022